Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis
- PMID: 22040834
- PMCID: PMC3298445
- DOI: 10.1016/j.ygyno.2011.09.039
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis
Abstract
Objective: The presence of T cells within the epithelial component of tumors, as histologic evidence of anti-tumor immunity, has been associated with a survival advantage in multiple studies across diverse patient cohorts. We performed a meta-analysis of studies evaluating the prognostic value of tumor-infiltrating lymphocytes (TIL) on survival among women with ovarian cancer and to investigate factors associated with variations in this effect, including patient characteristics, surgical outcomes, tumor histology, and study protocols.
Method: Published studies that evaluated the association between TIL and patient survival were identified. Descriptive statistics, outcome data, and study quality were extracted from studies that met inclusion criteria. Hazard ratios and 95% confidence intervals were pooled across studies using the random-effects model. Publication bias was investigated using a funnel plot and heterogeneity was assessed with subgroup analysis and I(2) statistics.
Results: Ten suitable studies comprising 1815 patients with ovarian cancer were analyzed. Our results demonstrate that a lack of intraepithelial TILs is significantly associated with a worse survival among patients (pooled HR: 2.24, 95% CI; 1.71-2.91). Variations in the prognostic value of TIL status based on debulking status, scoring method, and geographic regions were identified.
Conclusions: Intraepithelial TILs are a robust predictor of outcome in ovarian cancer and define a specific class of patients, whose distinct tumor biology should be taken into account in devising appropriate therapeutic strategies.
Copyright © 2011 Elsevier Inc. All rights reserved.
Conflict of interest statement
None.
Figures
Comment in
-
Killer T cells to the rescue in ovarian cancer.Gynecol Oncol. 2012 Feb;124(2):178-9. doi: 10.1016/j.ygyno.2011.12.434. Gynecol Oncol. 2012. PMID: 22264602 No abstract available.
Similar articles
-
Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.Gynecol Oncol. 2018 Oct;151(1):10-17. doi: 10.1016/j.ygyno.2018.07.025. Epub 2018 Aug 2. Gynecol Oncol. 2018. PMID: 30078505
-
The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.Oncotarget. 2017 Feb 28;8(9):15621-15631. doi: 10.18632/oncotarget.14919. Oncotarget. 2017. PMID: 28152503 Free PMC article.
-
Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.Clin Cancer Res. 2014 Jan 15;20(2):434-44. doi: 10.1158/1078-0432.CCR-13-1877. Epub 2013 Nov 4. Clin Cancer Res. 2014. PMID: 24190978
-
Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.BMC Cancer. 2016 Aug 26;16(1):687. doi: 10.1186/s12885-016-2732-0. BMC Cancer. 2016. PMID: 27566250 Free PMC article. Review.
-
Tumor infiltrating lymphocytes in ovarian cancer.Cancer Biol Ther. 2015;16(6):807-20. doi: 10.1080/15384047.2015.1040960. Epub 2015 Apr 20. Cancer Biol Ther. 2015. PMID: 25894333 Free PMC article. Review.
Cited by
-
Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins.J Immunol Res. 2020 Aug 4;2020:7375947. doi: 10.1155/2020/7375947. eCollection 2020. J Immunol Res. 2020. PMID: 32832572 Free PMC article.
-
Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer.Front Oncol. 2021 Feb 25;11:590414. doi: 10.3389/fonc.2021.590414. eCollection 2021. Front Oncol. 2021. PMID: 33718143 Free PMC article.
-
Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer.Cancers (Basel). 2020 Jul 2;12(7):1761. doi: 10.3390/cancers12071761. Cancers (Basel). 2020. PMID: 32630708 Free PMC article. Review.
-
Ovarian cancer.Nat Rev Dis Primers. 2016 Aug 25;2:16061. doi: 10.1038/nrdp.2016.61. Nat Rev Dis Primers. 2016. PMID: 27558151 Free PMC article. Review.
-
CD20+ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer.Oncoimmunology. 2015 Mar 19;4(4):e999536. doi: 10.1080/2162402X.2014.999536. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137418 Free PMC article.
References
-
- Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621–3627. - PubMed
-
- Nguyen TT, Wright JD, Powell MA, et al. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2008;18:1194–1199. - PubMed
-
- Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–213. - PubMed
-
- Hayashi K, Yonamine K, Masuko-Hongo K, et al. Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans. Gynecol Oncol. 1999;74:86–92. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous